Skip to main content

Advertisement

Table 1 Demographics, characteristics, and disease activity measures as observed on patients who entered the extension study

From: Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial

  Baseline Week 22 Week 36 Week 50
Original MTX (n = 8) Original MTX+TNFi (n = 18) p Original MTX (n = 8) Original MTX+TNFi (n = 18) p Original MTX (n = 8) Original MTX+TNFi (n = 16) p Original MTX (n = 6) Original MTX+TNFi (n = 10) p
Age 46 (13.1) 48.7 (10) NS          
Gender (male/female) 7/1 13/5 NS 7/1 13/5 NS 7/1 13/3 NS 5/1 9/1 NS
Disease duration < 2 years, n (%) 5 (62.5) 14 (77.8) NS 5 (62.5) 14 (77.8) NS 5 (62.5) 12 (75) NS 4 (66.7) 6 (60) NS
SJC 66, median (IQR) 3.5 (3–7.3) 7 (4–8.3) NS 0.5 (0–2) 0 (0–1) NS 1 (0.3–2) 0 (0–1.3) NS 0 (0–1.3) 0 (0–3.3) NS
TJC 68, median (IQR) 5 (4–13.8) 10 (4.8–14.3) NS 1 (0.3–3.3) 0 (0–3.3) NS 1.5 (0.3–2.8) 1.5 (0–4.5) NS 0 (0–1.5) 1.5 (0–4.3) NS
PASI score, median (IQR) 2.7 (0.5–6) 1.9 (0.8–3.8) NS 0.8 (0.4–1.7) 0 0.001 0.5 (0.5–1.8) 0 NS 1 (0.3–1.9) 0.6 (0–1.3) NS
PASI > 2.5, n (%) 4 (50) 8 (44.4) NS 1 (12.5) 0 NS 0 1 (6.3) NS 0 1 (10) NS
Pts with enthesitis, n (%) 0 2 (11.1) NS 1 (12.5) 1 (5.6) NS 1 (12.5) 3 (18.9) NS 0 1 (10) NS
Pts with dactylitis, n (%) 4 (50) 4 (22.2) NS 1 (12.5) 0 NS 4 (50) 1 (6.3) NS 1 (16.7) 1 (10) NS
ESR (mm/h), median (IQR) 15.5 (5.5–24.3) 20.5 (4.3–31.8) NS 7 (3.5–15.8) 2 (2–18) NS 5.5 (2–10.8) 5 (2–6.5) NS 5 (2.5–11.5) 6 (2–12) NS
CRP (mg/L), median (IQR) 9.5 (2.1–14) 4 (1.3–14.5) NS 3.1 (0.9–15) 1.1 (0.4–2.9) NS 1.8 (0.7–8) 1.5 (0.4–4) NS 4.2 (0.9–7.4) 2 (1–5) NS
VAS patient global (mm) 26.9 (17.8) 46.3 (24.9) NS 23.4 (25.9) 17.7 (17.6) NS 18.3 (20.9) 24.1 (23.8) NS 17.4 (15.2) 19.8 (20) NS
VAS patient pain (mm) 20 (15.8) 47.7 (26.1) 0.011 8.1 (12.7) 13.6 (17.5) NS 9.4 (8.7) 23 (21.6) NS 6.2 (4) 21 (27.1) NS
VAS physician (mm) 43.1 (14.0) 45.3 (15.6) NS 12.6 (10.2) 8.1 (9.3) NS 8.9 (8.1) 13.8 (19.6) NS 15.6 (12.1) 13 (17.5) NS
BASDAI 2.4 (1.8) 4.1 (1.9) 0.047 1.5 (1.6) 1.8 (1.5) NS 1.7 (1.5) 2 (1.7) NS 1.8 (1.7) 1.7 (1.4) NS